Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

Status:
Completed

Trial end date:
2017-09-12

Target enrollment:

Participant gender:

This study assessed pasireotide LAR efficacy on patients with non-functioning pituitary adenomas concerning tumor growth.

Phase 2

Novartis Pharmaceuticals

Pasireotide